Sisram Medical Ltd
復銳醫療科技有限公司*

(Incorporated in Israel with limited liability)

(Stock Code: 1696)

VOLUNTARY ANNOUNCEMENT

This announcement is made by Sisram Medical Ltd (the "**Company**") on a voluntary basis.

The Company is pleased to announce that the registration application of Profhilo® (the "**Product**"), an injectable product exclusively distributed by the Company in Mainland China, was accepted by the National Medical Products Administration (the "**NMPA**"). The Product is a buffered physiological solution of high molecular weight hyaluronic acid (H-HA) and low molecular weight hyaluronic acid (L-HA). It uses NAHYCO® patented mixing technology to bring a better anti-aging experience to beauty seekers and patients.

The Product has already been exclusively distributed in Israel, India and Hong Kong S.A.R through the Company's channels. In the event that the registration application is approved by the NMPA, it will enrich the Company's injectable product portfolio in Mainland China, promote the Company's product development and market penetration in the aesthetic field.

Shareholders and investors are advised to exercise caution when dealing in the securities of the Company.

On behalf of the Board
Sisram Medical Ltd
復銳醫療科技有限公司*
Yi LIU
Chairman

Hong Kong, 29 November 2023

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Yi LIU and Mr. Lior Moshe DAYAN as Executive Directors; Mr. Yifang WU and Ms. Rongli FENG as Non-Executive Directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as Independent Non-executive Directors.

* *for identification purpose only*